Vaxcyte slides as recent $1.15 billion financing weighs on shares

Vaxcyte (PCVX) is down 5.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued pressure from Vaxcyte’s large equity and convertible note financing, which can weigh on biotech shares because of dilution concerns and added supply. This could also be a bout of profit-taking as investors wait for late-October 2026 topline data from the company’s Phase 3 VAX-31 OPUS-1 trial. ([vaxcyte.gcs-web.com](https://vaxcyte.gcs-web.com/news-releases/news-release-details/vaxcyte-announces-closing-115-billion-public-offerings-common))

Details:

Vaxcyte said on October 9, 2026 that it closed concurrent public offerings totaling about $1.15 billion in gross proceeds. ([vaxcyte.gcs-web.com](https://vaxcyte.gcs-web.com/news-releases/news-release-details/vaxcyte-announces-closing-115-billion-public-offerings-common))

The deal included 8,584,375 common shares priced at $64.00, 400,000 pre-funded warrants, and $575 million of 1.50% convertible senior notes due 2032. ([vaxcyte.gcs-web.com](https://vaxcyte.gcs-web.com/news-releases/news-release-details/vaxcyte-announces-closing-115-billion-public-offerings-common))

The company disclosed estimated net proceeds of about $544.3 million from the equity offering and $558.7 million from the note offering, reinforcing the scale of the capital raise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1649094/000119312526419174/d150490d8k.htm))

Management plans to use the cash for VAX-31 clinical development, manufacturing scale-up, inventory build, and commercial preparation, while OPUS-1 topline data is expected by the end of October 2026. ([vaxcyte.gcs-web.com](https://vaxcyte.gcs-web.com/news-releases/news-release-details/vaxcyte-announces-closing-115-billion-public-offerings-common))

Sources:

Vaxcyte investor relations, SEC ([vaxcyte.gcs-web.com](https://vaxcyte.gcs-web.com/news-releases/news-release-details/vaxcyte-appoints-chief-medical-officer-and-chief-legal-officer))

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PCVX Insider Trading Activity

$PCVX insiders have traded $PCVX stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.

Here’s a breakdown of recent trading of $PCVX stock by insiders over the last 6 months:

GRANT PICKERING (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 19 sales selling 66,896 shares for an estimated $3,634,849.
JIM WASSIL (EVP, Chief Scientific Ofc, COO) has made 0 purchases and 15 sales selling 33,192 shares for an estimated $2,424,751.
ELVIA COWAN (SVP, Finance & CAO) sold 19,000 shares for an estimated $1,648,060
ANDREW GUGGENHIME (PRESIDENT AND CFO) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $1,641,716.
HARPREET S. DHALIWAL (Chief Technical Ops Officer) sold 17,000 shares for an estimated $935,068

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive PCVX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$PCVX Hedge Fund Activity

We have seen 175 institutional investors add shares of $PCVX stock to their portfolio, and 139 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 5,524,774 shares (+82.7%) to their portfolio in Q2 2026, for an estimated $321,155,112
FMR LLC added 4,360,046 shares (+26.4%) to their portfolio in Q2 2026, for an estimated $253,449,473
PARADIGM BIOCAPITAL ADVISORS LP removed 2,665,168 shares (-55.6%) from their portfolio in Q2 2026, for an estimated $154,926,215
PRICE T ROWE ASSOCIATES INC /MD/ added 2,012,570 shares (+206.1%) to their portfolio in Q2 2026, for an estimated $116,990,694
D. E. SHAW & CO., INC. removed 1,729,181 shares (-47.6%) from their portfolio in Q2 2026, for an estimated $100,517,291
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,464,812 shares (+inf%) to their portfolio in Q2 2026, for an estimated $85,149,521
WELLINGTON MANAGEMENT GROUP LLP added 1,386,968 shares (+24.7%) to their portfolio in Q2 2026, for an estimated $80,624,449

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$PCVX Congressional Stock Trading

Members of Congress have traded $PCVX stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $PCVX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 3 purchases worth up to $45,000 on 07/16, 05/13, 05/12 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.